4D Molecular Therapeutics Inc.

35.52+0.4000+1.14%Vol 30.36K1Y Perf -12.37%
Sep 23rd, 2021 14:04 DELAYED
BID35.20 ASK35.56
Open35.25 Previous Close35.12
Pre-Market- After-Market-
 - -%  - -
Target Price
57.50 
Analyst Rating
— — 0.00
Potential %
61.88 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
41.89 
Earnings Rating
Market Cap958.61M 
Earnings Date
11th Nov 2021
Alpha-0.06 Standard Deviation0.16
Beta1.36 

Today's Price Range

33.9135.91

52W Range

21.4055.11

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
3.97%
1 Month
21.35%
3 Months
41.73%
6 Months
-17.94%
1 Year
-12.37%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FDMT35.520.40001.14
AAPL146.911.06000.73
GOOG2 840.0021.23000.75
MSFT299.871.29000.43
XOM57.061.85003.35
WFC48.050.97002.06
JNJ165.661.73001.06
FB346.633.42001.00
GE103.675.13005.21
JPM161.555.64003.62
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.71-0.2860.56
Q01 2021--0.61-
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Nov 2021
Estimated EPS Next Report-0.83
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume30.36K
Shares Outstanding26.99M
Shares Float18.56M
Trades Count1.15K
Dollar Volume5.83M
Avg. Volume150.94K
Avg. Weekly Volume489.06K
Avg. Monthly Volume240.26K
Avg. Quarterly Volume163.84K

4D Molecular Therapeutics Inc. (NASDAQ: FDMT) stock closed at 35.12 per share at the end of the most recent trading day (a 0.31% change compared to the prior day closing price) with a volume of 99.12K shares and market capitalization of 958.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 78 people. 4D Molecular Therapeutics Inc. CEO is David Kirn.

The one-year performance of 4D Molecular Therapeutics Inc. stock is -12.37%, while year-to-date (YTD) performance is %. FDMT stock has a five-year performance of %. Its 52-week range is between 21.4 and 55.11, which gives FDMT stock a 52-week price range ratio of 41.89%

4D Molecular Therapeutics Inc. currently has a PE ratio of -4.50, a price-to-book (PB) ratio of 3.90, a price-to-sale (PS) ratio of 39.10, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -20.54%, a ROC of -21.77% and a ROE of -21.76%. The company’s profit margin is -%, its EBITDA margin is -220.00%, and its revenue ttm is $23.02 Million , which makes it $0.85 revenue per share.

Of the last four earnings reports from 4D Molecular Therapeutics Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.83 for the next earnings report. 4D Molecular Therapeutics Inc.’s next earnings report date is 11th Nov 2021.

The consensus rating of Wall Street analysts for 4D Molecular Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for 4D Molecular Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

4D Molecular Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

4D Molecular Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 38.48, ATR14 : 2.10, CCI20 : 119.02, Chaikin Money Flow : 0.13, MACD : 1.64, Money Flow Index : 74.33, ROC : 9.14, RSI : 64.36, STOCH (14,3) : 83.27, STOCH RSI : 0.49, UO : 59.05, Williams %R : -16.73), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of 4D Molecular Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.

CEO: David Kirn

Telephone: +1 510 505-2680

Address: 5858 Horton Street, Emeryville 94608, CA, US

Number of employees: 78

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

40%60%

Bearish Bullish

50%50%

News

Stocktwits